Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Feb 9;143(6):516-525.
doi: 10.1161/CIRCULATIONAHA.120.052186. Epub 2020 Nov 13.

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

Matthew M Y Lee  1   2   3 , Katriona J M Brooksbank  1 , Kirsty Wetherall  4 , Kenneth Mangion  1   2 , Giles Roditi  1   2   3 , Ross T Campbell  1   2   5 , Colin Berry  1   2   5 , Victor Chong  6 , Liz Coyle  1 , Kieran F Docherty  1   2 , John G Dreisbach  5 , Catherine Labinjoh  7 , Ninian N Lang  1   2 , Vera Lennie  8 , Alex McConnachie  4 , Clare L Murphy  9 , Colin J Petrie  1   10 , John R Petrie  1   3 , Iain A Speirits  11 , Steven Sourbron  12 , Paul Welsh  1 , Rosemary Woodward  2 , Aleksandra Radjenovic  1 , Patrick B Mark  1   2 , John J V McMurray  1   2 , Pardeep S Jhund #  1   2 , Mark C Petrie #  1   3   5 , Naveed Sattar #  1   3
Affiliations
Randomized Controlled Trial

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

Matthew M Y Lee et al. Circulation. .

Abstract

Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced ejection fraction (HFrEF). However, their effects on cardiac structure and function in HFrEF are uncertain.

Methods: We designed a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR-DM-HF trial [Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus, or Prediabetes, and Heart Failure]) to investigate the cardiac effects of empagliflozin in patients in New York Heart Association functional class II to IV with a left ventricular (LV) ejection fraction ≤40% and type 2 diabetes or prediabetes. Patients were randomly assigned 1:1 to empagliflozin 10 mg once daily or placebo, stratified by age (<65 and ≥65 years) and glycemic status (diabetes or prediabetes). The coprimary outcomes were change from baseline to 36 weeks in LV end-systolic volume indexed to body surface area and LV global longitudinal strain both measured using cardiovascular magnetic resonance. Secondary efficacy outcomes included other cardiovascular magnetic resonance measures (LV end-diastolic volume index, LV ejection fraction), diuretic intensification, symptoms (Kansas City Cardiomyopathy Questionnaire Total Symptom Score, 6-minute walk distance, B-lines on lung ultrasound, and biomarkers (including N-terminal pro-B-type natriuretic peptide).

Results: From April 2018 to August 2019, 105 patients were randomly assigned: mean age 68.7 (SD, 11.1) years, 77 (73.3%) male, 82 (78.1%) diabetes and 23 (21.9%) prediabetes, mean LV ejection fraction 32.5% (9.8%), and 81 (77.1%) New York Heart Association II and 24 (22.9%) New York Heart Association III. Patients received standard treatment for HFrEF. In comparison with placebo, empagliflozin reduced LV end-systolic volume index by 6.0 (95% CI, -10.8 to -1.2) mL/m2 (P=0.015). There was no difference in LV global longitudinal strain. Empagliflozin reduced LV end-diastolic volume index by 8.2 (95% CI, -13.7 to -2.6) mL/m2 (P=0.0042) and reduced N-terminal pro-B-type natriuretic peptide by 28% (2%-47%), P=0.038. There were no between-group differences in other cardiovascular magnetic resonance measures, diuretic intensification, Kansas City Cardiomyopathy Questionnaire Total Symptom Score, 6-minute walk distance, or B-lines.

Conclusions: The sodium-glucose cotransporter 2 inhibitor empagliflozin reduced LV volumes in patients with HFrEF and type 2 diabetes or prediabetes. Favorable reverse LV remodeling may be a mechanism by which sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization and mortality in HFrEF. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03485092.

Keywords: clinical trial; diabetes mellitus; empagliflozin; heart failure; magnetic resonance imaging; myocardium; sodium-glucose transporter 2 inhibitors; ventricular remodeling.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Change in coprimary cardiovascular magnetic resonance outcomes from baseline to week 36. Mean (95% CI). *Treatment effect calculated using an analysis of covariance model adjusted for treatment group, age at baseline, diabetes status, and baseline value. LVESVi indicates left ventricular end-systolic volume index; and LV GLS, left ventricular global longitudinal strain.
Figure 2.
Figure 2.
Change in secondary cardiovascular magnetic resonance outcomes from baseline to week 36. *Treatment effect calculated using an analysis of covariance model adjusted for treatment group, age at baseline, diabetes status, and baseline value. LAVi indicates left atrial volume index; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVGFI, left ventricular global function index; and LVMi, left ventricular mass index.
See this image and copyright information in PMC

Comment in

References

    1. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56:392–406. doi: 10.1016/j.jacc.2010.05.011 - PMC - PubMed
    1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569–582. doi: 10.1016/s0735-1097(99)00630-0 - PubMed
    1. Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Raval U, Webster J, Murray GD, Coats AJ, Cleland JG, Pennell DJ; CHRISTMAS Study Steering Committee and Investigators. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart. 2004;90:760–764. doi: 10.1136/hrt.2003.015552 - PMC - PubMed
    1. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36:2072–2080. doi: 10.1016/s0735-1097(00)01006-8 - PubMed
    1. Tardif JC, O’Meara E, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K; SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507–2515. doi: 10.1093/eurheartj/ehr311 - PMC - PubMed

Publication types

MeSH terms

Associated data